NEUMORA THERAPEUTICS, INC.

Insiders Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Real-time Estimate Cboe BZX Other stock markets 09:43:57 2024-05-22 am EDT			5-day change	1st Jan Change
9.295 ^USD	-1.64%		-1.36%	-44.57%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22	MT
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22	CI
Neumora Therapeutics, Inc. Appoints Jason Duncan as Chief Legal Officer	Dec. 12	CI
Neumora Therapeutics Insider Bought Shares Worth $1,127,064, According to a Recent SEC Filing	23-09-26	MT
Neumora Therapeutics Insider Bought Shares Worth $25,500,000, According to a Recent SEC Filing	23-09-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW